摘要
目的评价阿帕替尼治疗晚期肺癌的近期临床效果。方法回顾性分析2017年6月~2018年10月芜湖市第二人民医院收治的12例晚期肺癌并采用阿帕替尼治疗患者的临床资料,每4周为1周期,评价临床疗效,记录不良反应并指导防治,连续评价3周期。结果 1周期后疾病控制率为91.67%,2周期时疾病控制率为63.64%,3周期时疾病控制率为42.86%,不良反应中以蛋白尿和痰中带血最常见,以痰中带血最严重。结论阿帕替尼治疗晚期肺癌近期效果显著,随着治疗时间延长,效果呈下降趋势。不良反应一般可耐受,值得临床推广。
Objective To evaluate the clinical efficacy of Apatinib in the treatment of advanced lung cancer. Methods The clinical data of 12 patients with advanced lung cancer treated with Apatinib from June 2017 to October 2018 in Second People′s Hospital of Wuhu were retrospectively analyzed, 4 weeks for one cycle. The clinical efficacy was evaluated, adverse reactions were recorded, prevention and treatment were guided, and 3 consecutive cycles were evaluated. Results The disease control rate was 91.67% after one cycle, 63.64% at two cycles and 42.86% at three cycles. Proteinuria and blood in sputum were the most common adverse reactions, and blood in sputum was the most serious. Conclusion The short-term efficacy of Apatinib in the treatment of advanced lung cancer is remarkable. With the prolongation of treatment time, the efficacy shows a downward trend. Adverse reactions are generally tolerable and worthy of clinical promotion.
作者
李超群
王秀明
朱凌燕
LI Chaoqun;WANG Xiuming;ZHU Lingyan(Department of Oncology, the Second People′s Hospital of Wuhu, Anhui Province, Wuhu 241000, China)
出处
《中国医药导报》
CAS
2019年第17期137-139,155,共4页
China Medical Herald
关键词
阿帕替尼
晚期肺癌
抗血管生成
临床疗效
不良反应
Apatinib
Advanced lung cancer
Anti-angiogenesis
Clinical efficacy
Adverse reactions
